Furl http://www.furl.net/ http://backend.userland.com/rss http://www.furl.net/member/cooleydd.rss Furl archive. Sat, 05 Jul 2008 11:11:21 GMT http://www.furl.net/item/34444842/forward http://www.furl.net/item/34444842 Tue, 10 Jun 2008 19:39:31 GMT 4. Hormonal Ablation Treatment 4. Radiation - External Beam Castration therapy adjuvant to radiotherapy can significantly improve overall survival compared with radiotherapy alone in patients with locally advanced prostate cancer. Although many of the adverse effects of castration therapy are manageable, they can have a detrimental effect on quality of life. Here we evaluate the efficacy and tolerability of the non-castration-based therapy bicalutamide ('Casodex') 150 mg adjuvant to radiotherapy in patients with T1-4, M0, any n prostate cancer. 3 http://www.furl.net/item/34444772/forward http://www.furl.net/item/34444772 Tue, 10 Jun 2008 19:33:07 GMT 4. Hormonal Ablation Treatment We determined the testosterone castration level with clinical relevance in patients with prostate cancer on continuous androgen deprivation therapy. Secondary objectives were to analyze the role of associated bicalutamide in breakthrough increases of serum testosterone in these patients and the possible benefit of maximal androgen blockade. 3 http://www.furl.net/item/34298572/forward http://www.furl.net/item/34298572 These were all T1 patients and I would guess they were using 3dEBRT - the results should be about the same with IMRT. That was an interesting Abstract. Notice the biochemical failure rates at 7 years of around 54% and 45% BUT no differenced in clinical failure or overall survival. Radiation therapy as a primary therapy is a long ways from being a treatment of choice with these kinds of figures. Dose escalation shows better biochemical failure but not clinical failure or survival. One wonders if these patients were not treated at all if the survival figures would be any different. If you would project these using 0.2 as biochemical failure the results would be down in the area of 30%. So we have better freedom from biochemical failure in higher dosages but with higher side effects and no better clinical failure or survival at 7 years. Pretty sorry state of affairs if you ask me. Wed, 04 Jun 2008 14:17:07 GMT 4. Radiation - External Beam To update the analysis of the Dutch dose-escalation trial of radiotherapy for prostate cancer. 3 http://www.furl.net/item/34097931/forward http://www.furl.net/item/34097931 Thu, 29 May 2008 03:52:38 GMT 4. Alternative/CAM/Supplemental/Diet Prostate cancer is an ideal target for chemoprevention strategies that, at present, may be the best approach, according to a group of Italian researchers. They cite a growing body of evidence that compounds from green tea (catechins: the most common are EGCG, EGC, ECG and EC) might posses anti-tumor activity. 3 http://www.furl.net/item/34097896/forward http://www.furl.net/item/34097896 Thu, 29 May 2008 03:50:20 GMT 4. Watchful Waiting/Active Surveillance Active surveillance (AS), or watchful waiting, is an accepted management strategy for selected men with prostate cancer (PCa). These investigators examined clinical and demographic profiles of men participating in a large, contemporary, prospective cohort study who elected to pursue AS for initial management. 3 http://www.furl.net/item/33963926/forward http://www.furl.net/item/33963926 Sat, 24 May 2008 14:57:25 GMT 4. Alternative/CAM/Supplemental/Diet Data exist that demonstrate isoflavones' potent antiproliferative effects on prostate cancer cells. We evaluated the efficacy of isoflavone in patients with PSA recurrent prostate cancer after prior therapy. We postulated that isoflavone therapy would slow the rate of rise of serum PSA. 3 http://www.furl.net/item/33963869/forward http://www.furl.net/item/33963869 Sat, 24 May 2008 14:54:36 GMT 4. Surgery Open, Robotic, Laparoscopic They conclude that RALP was associated with significantly higher early complication rates compared to RRP; however, there was no difference in long-term continence or potency rates between the two techniques. Furthermore, early oncologic outcomes were similar with no difference in margin positivity or short-term PFS between the two groups. 3 http://www.furl.net/item/33963828/forward http://www.furl.net/item/33963828 Sat, 24 May 2008 14:52:33 GMT 4. Surgery Open, Robotic, Laparoscopic Previous studies have suggested that prostate cancer in young men may behave more aggressively. These reports have recently been refuted. There remains a scarcity of data on the biochemical outcome after radical prostatectomy specifically for men in their 30’s. 3 http://www.furl.net/item/33963730/forward http://www.furl.net/item/33963730 Sat, 24 May 2008 14:46:41 GMT 1b. Prevention and Screening The aim of this study was to examine associations of smoking at the time of diagnosis with the risk of prostate cancer death in a population-based cohort of men with prostate cancer. 3 http://www.furl.net/item/33963725/forward http://www.furl.net/item/33963725 Sat, 24 May 2008 14:46:34 GMT 1b. Prevention and Screening The aim of this study was to examine associations of smoking at the time of diagnosis with the risk of prostate cancer death in a population-based cohort of men with prostate cancer. 3